fda glp-1 safety warning september 2025 Targets and Peptide Compounding, Advertising and 'Research Use Only' Labeling fda semaglutide warning september 2025

Professor De Cristofaro, Dr

2025;37(1):187-204.e7

The minimum recommended waiting period is six weeks postpartum for uncomplicated vaginal deliveries

GLP-1 microdosing may help certain patients manage weight gain and metabolic changes often associated with menopause, but it is not a primary treatment for direct symptoms like hot flashes or mood swings

Lancet 376:431439 Boggiano MM, Chandler PC, Oswald KD, Rodgers RJ, Blundell JE, Ishii Y, Beattie AH, Holch P, Allison DB, Schindler M, Arndt K, Rudolf K, Mark M, Schoelch C, Joost HG, Klaus S, Thone-Reineke C, Benoit SC, Seeley RJ, Beck-Sickinger AG, Koglin N, Raun K, Madsen K, Wulff BS, Stidsen CE, Birringer M, Kreuzer OJ, Deng XY, Whitcomb DC, Halem H, Taylor J, Dong J, Datta R, Culler M, Ortmann S, Castaneda TR, Tschop M (2005) PYY3-36 as an anti-obesity drug target